398 related articles for article (PubMed ID: 16010590)
61. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.
Yin MB; Guimaraes MA; Zhang ZG; Arredondo MA; Rustum YM
Cancer Res; 1992 Nov; 52(21):5900-5. PubMed ID: 1394217
[TBL] [Abstract][Full Text] [Related]
62. Thymidylate synthase inhibitors.
Touroutoglou N; Pazdur R
Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
[TBL] [Abstract][Full Text] [Related]
63. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
[TBL] [Abstract][Full Text] [Related]
64. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
65. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
66. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
Bijnsdorp IV; Peters GJ; Temmink OH; Fukushima M; Kruyt FA
Int J Cancer; 2010 May; 126(10):2457-68. PubMed ID: 19816940
[TBL] [Abstract][Full Text] [Related]
67. A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro.
Strømhaug A; Warren DJ
Cancer Chemother Pharmacol; 2000; 45(6):450-6. PubMed ID: 10854131
[TBL] [Abstract][Full Text] [Related]
68. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
69. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
70. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
[TBL] [Abstract][Full Text] [Related]
71. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.
Webley SD; Welsh SJ; Jackman AL; Aherne GW
Br J Cancer; 2001 Aug; 85(3):446-52. PubMed ID: 11487279
[TBL] [Abstract][Full Text] [Related]
72. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
73. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid.
Smith GK; Amyx H; Boytos CM; Duch DS; Ferone R; Wilson HR
Cancer Res; 1995 Dec; 55(24):6117-25. PubMed ID: 8521402
[TBL] [Abstract][Full Text] [Related]
74. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Peters GJ; van Triest B; Backus HH; Kuiper CM; van der Wilt CL; Pinedo HM
Eur J Cancer; 2000 May; 36(7):916-24. PubMed ID: 10785598
[TBL] [Abstract][Full Text] [Related]
75. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies.
Webber S; Bartlett CA; Boritzki TJ; Hillard JA; Howland EF; Johnston AL; Kosa M; Margosiak SA; Morse CA; Shetty BV
Cancer Chemother Pharmacol; 1996; 37(6):509-17. PubMed ID: 8612303
[TBL] [Abstract][Full Text] [Related]
76. Antifolates targeted specifically to the folate receptor.
Jackman AL; Theti DS; Gibbs DD
Adv Drug Deliv Rev; 2004 Apr; 56(8):1111-25. PubMed ID: 15094210
[TBL] [Abstract][Full Text] [Related]
77. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
78. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
Kabeshima Y; Kubota T; Watanabe M; Saikawa Y; Nishibori H; Hasegawa H; Kitajima M
Anticancer Res; 2002; 22(6A):3245-52. PubMed ID: 12530071
[TBL] [Abstract][Full Text] [Related]
79. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ
Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800
[TBL] [Abstract][Full Text] [Related]
80. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Kelland LR; Kimbell R; Hardcastle A; Aherne GW; Jackman AL
Eur J Cancer; 1995 Jun; 31A(6):981-6. PubMed ID: 7646933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]